Skip to main content

Table 3 Meta-analysis of VDR ApaI polymorphism and prostate cancer risk

From: Role of vitamin D receptor gene Cdx2 and Apa1 polymorphisms in prostate cancer susceptibility: a meta-analysis

   Homozygote (AA vs. aa) Heterozygote (Aa vs. aa) Dominant model (AA + Aa vs. aa) Recessive model (AA vs. Aa + aa)
Analysis N OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%)
Overall 9 0.97 (0.76–1.25) 0.85 51.1 1.00 (0.88–1.13) 0.99 28.8 0.98 (0.87–1.10) 0.79 0 0.97 (0.85–1.01) 0.64 0
Ethnicity
Caucasian 4 0.81 (0.66–1.01) 0.06 11.0 1.01 (0.85–1.19) 0.91 20.8 0.94 (0.81–1.10) 0.46 20.8 0.92 (0.78–1.06) 0.25 0
African American 2 1.54 (0.74–3.19) 0.24 57.9 1.16 (0.84–1.60) 0.35 0 1.27 (0.94–1.72) 0.12 0 0.92 (0.65–1.29) 0.63 0
Asian 6 1.05 (0.69–1.58) 0.82 36.2 0.90 (0.71–1.14) 0.40 49.0 0.93 (0.76–1.16) 0.56 0 1.24 (0.92–1.66) 0.14 0
Source of control
PB 8 1.03 (0.77–1.38) 0.82 60.1 1.05 (0.91–1.20) 0.52 42.9 1.02 (0.90–1.16) 0.72 0 0.97 (0.85–1.11) 0.64 17.8
HB 4 0.82 (0.50–1.34) 0.43 29.3 0.83 (0.63–1.10) 0.20 0 0.84 (0.65–1.09) 0.18 0 0.98 (0.69–1.38) 0.92 0
HWE in controls
Yes 10 0.96 (0.76–1.21) 0.733 36.6 1.01 (0.89–1.15) 0.90 0 0.99 (0.87–1.12) 0.86 0 0.93 (0.82–1.06) 0.29 0
No 2 0.86 (0.19–3.86) 0.84 86.7 0.91 (0.59–1.40) 0.66 85.6 0.98 (0.88–1.10) 0.74 0 1.56 (0.99–2.46) 0.05 0
  1. P P values for Z test, OR odds ratio, CI confidence intervals, HB hospital–based studies, PB population-based studies, HWE Hardy–Weinberg equilibrium, NR not reported